Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery.

Scalp hair loss is an underreported adverse event of somatostatin analogs therapy that in severe cases may require treatment withdrawal. It can be related to an acute decrease in GH/IGF-1 levels, but a direct effect cannot be ruled out.